In Q1'26, CLS's operating expenses reached a total of $158.6M USD, with R&D expenses at $41.2M USD and SG&A expenses at $117.4M USD, marking a significant increase from the previous quarter and reflecting heightened investment in administrative and research activities. Over the period from Q2'23 to Q1'26, total operating expenses exhibited volatile growth, rising from $83.4M USD in Q2'23 to a peak of $158.6M USD in Q1'26, driven primarily by sharp escalations in SG&A expenses—such as the jump to $112.5M USD in Q1'25—while R&D expenses showed a more pronounced upward trajectory from $14.3M USD in Q2'23 to $41.2M USD in Q1'26, with notable spikes in Q2'25 and Q3'25; this pattern suggests expanding operational scale amid fluctuating quarterly demands, though periods of decline, like Q4'24's dip to $79.7M USD total, indicate intermittent cost controls.